+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naive advanced non-small-cell lung cancer in the era of third-generation agents



Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naive advanced non-small-cell lung cancer in the era of third-generation agents







The aim was to compare the efficacy between doublets of third-generation agents (non-platinum) and doublets of platinum plus a third-generation agent (platinum-based) for chemotherapy-na ve advanced non-small-cell lung cancer (NSCLC). We conducted a literature-based meta-analysis to compare the efficacy between doublets of third-generation agents and doublets of platinum plus a third-generation agent for chemotherapy-na ve advanced NSCLC. The primary end point was overall survival, and the secondary end points were progression-free survival (PFS) and response rate. Subgroup analyses were also conducted by different non-platinum doublet regimens or different platinum-based doublets. A descriptive review for toxicity was performed. Sixteen randomized controlled trials were identified ultimately. demonstrated that the efficacy of non-platinum doublets was comparable with platinum-based doublets according to the overall survival (HR = 1.03, 95 % CI = 0.98 1.08, p = 0.29). Subgroup analyses by different non-platinum doublets also showed the efficacy of all the third-generation doublets, such as vinorelbine plus gemcitabine, vinorelbine plus paclitaxel, gemcitabine plus paclitaxel, and gemcitabine plus docetaxel, was comparable with platinum-based doublets (HR = 1.00, 95 % CI = 0.78 1.27, p = 0.98; HR = 0.97, 95 % CI = 0.80 1.18, p = 0.79; HR = 1.05, 95 % CI = 0.99 1.12, p = 0.11; HR = 1.01, 95 % CI = 0.92 1.10, p = 0.87; respectively). Subgroup analyses by different platinum-based doublets indicated that the efficacy of the third-generation doublets were equal to both cisplatin-based doublets and carboplatin-based doublets (HR = 1.08, 95 % CI = 1.00 1.17, p = 0.05; HR = 1.00, 95 % CI = 0.94 1.05, p = 0.94; respectively). The secondary end points indicated that platinum-based doublets might have an advantage in PFS but not in response rate (HR = 1.06, 95 % CI = 1.01 1.12, p = 0.03; RR = 0.99, 95 % CI = 0.90 1.08, p = 0.81; respectively). Non-platinum doublets were as effective as platinum-based doublets with different toxicity profile for chemotherapy-na ve advanced NSCLC in the era of third-generation agents.

(PDF emailed within 1 workday: $29.90)

Accession: 036546672

Download citation: RISBibTeXText


Related references

Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents. Journal of Cancer Research and Clinical Oncology 139(1): 25-38, 2013

Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets. Cancer ChemoTherapy and Pharmacology 67(1): 35-39, 2011

Efficacy analysis of third-generation plus platinum doublets in the first-line chemotherapy of advanced non-small cell lung cancer. Zhonghua Yi Xue Za Zhi 92(22): 1527-1531, 2013

The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. Lung Cancer 62(2): 242-252, 2008

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. Journal of Clinical Oncology 20(21): 4285-4291, 2002

Incidence of chemotherapy discontinuation and characteristics of elderly patients with non-small cell lung cancer treated with platinum-based doublets. Contemporary Oncology 18(5): 340-343, 2014

Outcome of advanced non-small cell lung cancer patients treated in a single institution with first generation platinum doublets. Using a retrospective analysis to help decisions in resource allocation. Journal of Clinical Oncology 23(16_Suppl): 7342-7342, 2016

P-345 Outcome of advanced non-small cell lung cancer patients treatedin a single institution with first generation platinum doublets. Using a retrospective analysis to help decisions in resource allocation. Lung Cancer 49: S206-S207, 2005

Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis. International Journal of Cancer 142(8): 1676-1688, 2017

Hospital Costs Associated with Platinum-Based Doublets in the First-Line Setting for Advanced Non-Squamous Non-Small Cell Lung Cancer in China: A Retrospective Cohort Study. Value in Health 17(7): A734, 2014

Platinum doublets as first-line treatment for elderly patients with advanced non-small cell lung cancer. Tumori 99(6): 650-655, 2014

Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. International Journal of Gynecological Cancer 19 Suppl 2: S63-S67, 2010

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. British Journal of Cancer 107(8): 1277-1285, 2012

Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study. Bmc Cancer 14: 940, 2015

Real-world hospital costs for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer in Chinese patients: a retrospective cohort study. Clinicoeconomics and Outcomes Research 8: 97-111, 2016